Patents by Inventor Mike De Leeuw
Mike De Leeuw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10239991Abstract: A bioresorbable triblock copolymer according to Formula 1 R-B-A-B-R??(1) wherein A is a hydrophilic polymer, B a hydrophobic polymer and R are end-groups, wherein R is H or a C1-C30 organic moiety and wherein the copolymer is fluid in a temperature range of 0° C. to 37° C. A pharmaceutical composition including the triblock copolymer and at least one therapeutically active agent. The copolymer and pharmaceutical composition can be used for forming a depot in a human or animal body or as medical device.Type: GrantFiled: April 29, 2015Date of Patent: March 26, 2019Assignee: INGELL TECHNOLOGIES HOLDING B.V.Inventors: Ronald Meijboom, Theo Flipsen, Mike De Leeuw
-
Patent number: 9901554Abstract: A special class of drug-depot forming triblock copolymers which are very suitable for the loading, containment and releasing of sensitive drugs such as proteins from biodegradable, injectable drug depots. How to visualize these depots for various imaging related purposes is described. A composition comprising a tri-block copolymer according to formula 1 B-A-B (1), wherein A stands for a linear poly-(ethylene glycol) block and wherein B stands for wherein B stands for a poly(lactide-co-?-caprolactone) block, wherein the hydroxyl end-groups of the tri-block copolymer are at least partially acylated with an optionally substituted acyl having 2 to 12 C-atoms, C-atoms of the substituents included; an active ingredient, preferably a pharmaceutically active ingredient and a solvent, wherein the block ratio of the tri-block copolymer, which ratio is defined as the ratio between the sum of the average molecular weight of the B-blocks and the sum of the average molecular weight of the A-block ranges from 1.4 to 3.5.Type: GrantFiled: April 2, 2012Date of Patent: February 27, 2018Assignee: INGELL TECHNOLOGIES HOLDING B.V.Inventors: Peter Bruin, Audrey Petit, Mike De Leeuw, Martin Piest, Ronald Meijboom
-
Patent number: 9795679Abstract: Simple mixing/blending of a special class of drug-depot forming tri-block copolymers polymers, with the opportunity to cost-effectively tailor drug delivery performances of such biodegradable, injectable depots in a clinical and an industrial setting. How to visualize these depots for various imaging related purposes is described.Type: GrantFiled: April 2, 2012Date of Patent: October 24, 2017Assignee: INGELL TECHNOLOGIES HOLDING B.V.Inventors: Audrey Petit, Peter Bruin, Mike De Leeuw, Ronald Meijboom
-
Publication number: 20170066874Abstract: A bioresorbable triblock copolymer according to Formula 1 R-B-A-B-R??(1) wherein A is a hydrophilic polymer, B a hydrophobic polymer and R are end-groups, wherein R is H or a C1-C30 organic moiety and wherein the copolymer is fluid in a temperature range of 0° C. to 37° C. A pharmaceutical composition including the triblock copolymer and at least one therapeutically active agent. The copolymer and pharmaceutical composition can be used for forming a depot in a human or animal body or as medical device.Type: ApplicationFiled: April 29, 2015Publication date: March 9, 2017Inventors: Ronald MEIJBOOM, Theo FLIPSEN, Mike DE LEEUW
-
Publication number: 20160228377Abstract: This disclosure is in the field of medical therapy; in particular, it concerns the use of encapsulated cells in cell therapy. More in particular, this disclosure relates to the second medical use of a composition comprising encapsulated cells. Even more in particular, the disclosure relates to the use of a foreign body, suitable for implantation into a subject at a predefined location, wherein the foreign body comprises cells encapsulated in high-M alginate for inducing or stimulating angiogenesis.Type: ApplicationFiled: September 19, 2014Publication date: August 11, 2016Applicant: Beta-Cell NVInventors: Myriam Lea Willy Bomans, Mike De Leeuw
-
Patent number: 9364544Abstract: Amphiphilic triblock copolymers B-A-B, wherein A is a linear poly(ethylene glycol) block, having a number average molecular weight (Mn) of between 900 and 3000 Daltons, determined with size exclusion chromatography; wherein B are hydrophobic blocks with at least two cyclic monomers selected from the group consisting of glycolide, lactide, 1,3-dioxan-2-one, 5,5-dimethyl-1,3-dioxan-2-one, 1,4-dioxan-2-one, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, each B-block having a number average molecular weight (Mn) of between 400 and 2000 Daltons, determined with size exclusion chromatography; and wherein 25% to 100% of the polymer hydroxyl end-groups are covalently modified with at least one derivative of a C2-C20 fatty acid. The invention also relates to compositions with such polymers and the use thereof.Type: GrantFiled: September 14, 2015Date of Patent: June 14, 2016Assignee: Ingell Technologies Holding B.V.Inventors: Sebastien Jerome Pierre, Mike De Leeuw
-
Publication number: 20160000922Abstract: Amphiphilic triblock copolymers B-A-B, wherein A is a linear poly(ethylene glycol) block, having a number average molecular weight (Mn) of between 900 and 3000 Daltons, determined with size exclusion chromatography; wherein B are hydrophobic blocks with at least two cyclic monomers selected from the group consisting of glycolide, lactide, 1,3-dioxan-2-one, 5,5-dimethyl-1,3-dioxan-2-one, 1,4-dioxan-2-one, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, each B-block having a number average molecular weight (Mn) of between 400 and 2000 Daltons, determined with size exclusion chromatography; and wherein 25% to 100% of the polymer hydroxyl end-groups are covalently modified with at least one derivative of a C2-C20 fatty acid. The invention also relates to compositions with such polymers and the use thereof.Type: ApplicationFiled: September 14, 2015Publication date: January 7, 2016Inventors: SEBASTIEN JEROME PIERRE, MIKE DE LEEUW
-
Patent number: 9168221Abstract: Amphiphilic triblock copolymers B-A-B, wherein A is a linear poly(ethylene glycol) block, having a number average molecular weight (Mn) of between 900 and 3000 Daltons, determined with size exclusion chromatography; wherein B are hydrophobic blocks with at least two cyclic monomers selected from the group consisting of glycolide, lactide, 1,3-dioxan-2-one, 5,5-dimethyl-1,3-dioxan-2-one, 1,4-dioxan-2-one, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, each B-block having a number average molecular weight (Mn) of between 400 and 2000 Daltons, determined with size exclusion chromatography; and wherein 25% to 100% of the polymer hydroxyl end-groups are covalently modified with at least one derivative of a C2-C20 fatty acid. The invention also relates to compositions with such polymers and the use thereof.Type: GrantFiled: January 7, 2011Date of Patent: October 27, 2015Assignee: INGELL TECHNOLOGIES HOLDING B.V.Inventors: Mike de Leeuw, Sebastien Jerome Pierre
-
Publication number: 20150165042Abstract: Simple mixing/blending of a special class of drug-depot forming tri-block copolymers polymers, with the opportunity to cost-effectively tailor drug delivery performances of such biodegradable, injectable depots in a clinical and an industrial setting. How to visualize these depots for various imaging related purposes is described.Type: ApplicationFiled: April 2, 2012Publication date: June 18, 2015Applicant: Ingell Technologies Holding B.V.Inventors: Audrey Petit, Peter Bruin, Mike De Leeuw, Ronald Meijboom
-
Patent number: 8962666Abstract: The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is preferably selected from the group consisting of agents that stimulate chondrogenic differentiation and/or cartilage matrix synthesis; agents that inhibit osteogenesis and/or hypertrophy, anti-inflammatory agents, agents that inhibit apoptosis of chondrocytes, agents that inhibit senescence of chondrocytes and agents that enhance lubrication of a joint.Type: GrantFiled: November 14, 2012Date of Patent: February 24, 2015Assignees: Maastricht University, Academic Hospital MaastrichtInventors: Peter Joseph Emans, Lodewijk Willem Van Rhijn, Tim Johannes Maria Welting, Mike De Leeuw
-
Publication number: 20140219923Abstract: A special class of drug-depot forming triblock copolymers which are very suitable for the loading, containment and releasing of sensitive drugs such as proteins from biodegradable, injectable drug depots. How to visualize these depots for various imaging related purposes is described. A composition comprising a tri-block copolymer according to formula 1 B-A-B (1), wherein A stands for a linear poly-(ethylene glycol) block and wherein B stands for wherein B stands for a poly(lactide-co-?-caprolactone) block, wherein the hydroxyl end-groups of the tri-block copolymer are at least partially acylated with an optionally substituted acyl having 2 to 12 C-atoms, C-atoms of the substituents included; an active ingredient, preferably a pharmaceutically active ingredient and a solvent, wherein the block ratio of the tri-block copolymer, which ratio is defined as the ratio between the sum of the average molecular weight of the B-blocks and the sum of the average molecular weight of the A-block ranges from 1.4 to 3.5.Type: ApplicationFiled: April 2, 2012Publication date: August 7, 2014Applicant: INGELL TECHNOLOGIES HOLDING B.V.Inventors: Peter Bruin, Audrey Petit, Mike De Leeuw, Martin Piest, Ronald Meijboom
-
Publication number: 20130017189Abstract: Amphiphilic triblock copolymers B-A-B, wherein A is a linear poly(ethylene glycol) block, having a number average molecular weight (Mn) of between 900 and 3000 Daltons, determined with size exclusion chromatography; wherein B are hydrophobic blocks with at least two cyclic monomers selected from the group consisting of glycolide, lactide, 1,3-dioxan-2-one, 5,5-dimethyl-1,3--dioxan-2-one, 1,4-dioxan-2-one, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, each B-block having a number average molecular weight (Mn) of between 400 and 2000 Daltons, determined with size exclusion chromatography; and wherein 25% to 100% of the polymer hydroxyl end-groups are covalently modified with at least one derivative of a C2-C20 fatty acid. The invention also relates to compositions with such polymers and the use thereof.Type: ApplicationFiled: January 7, 2011Publication date: January 17, 2013Applicant: INGELL TECHNOLOGIES HOLDING B.V.Inventors: Sebastien Jerome Pierre, Mike De Leeuw
-
Publication number: 20100215731Abstract: The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is preferably selected from the group consisting of agents that stimulate chondrogenic differentiation and/or cartilage matrix synthesis; agents that inhibit osteogenesis and/or hypertrophy, anti-inflammatory agents, agents that inhibit apoptosis of chondrocytes, agents that inhibit senescence of chondrocytes and agents that enhance lubrication of a joint.Type: ApplicationFiled: February 19, 2010Publication date: August 26, 2010Applicants: MAASTRICHT UNIVERSITY, ACADEMIC HOSPITAL MAASTRICHTInventors: Peter Joseph Emans, Lodewijk Willem Van Rhijn, Tim Johannes Maria Welting, Mike De Leeuw